The Baker administration is keeping a lockdown on information pertaining to its selection of a high-ranking official to continue carrying out the $1 billion, 10-year life sciences law approved by Gov. Deval Patrick in 2008.
Framingham biopharmaceutical firm LFB USA has pinned plans to build a new 65,000-square-foot manufacturing and laboratory facility in Marlborough in part on the expectation that its drug, ATryn, will soon receive FDA approval for the treatment of preeclampsia.
Worcester Polytechnic Institute has joined a biomanufacturing industry trade group to help develop technology education and training curricula, the school announced last week.
A Framingham-based biopharmaceutical company wants to expand its operations in Marlborough, with plans to add 50 jobs within the next decade, according to documents provided to the Worcester Business Journal.
Paul K. Wotton, president and CEO of Ocata Therapeutics, rang the opening bell at the NASDAQ Marketside in New York City Wednesday morning.
"We are pleased to have been invited to open the NASDAQ and as a leader in regenerative ophthalmology are delighted to be part of this leading stock exchange," Paul K. Wotton, president and CEO of Ocata Therapeutics, said in a statement released before the ceremony.
Legislation repealing the 2.3-percent federal tax on medical devices cleared the U.S. House Thursday on a vote of 280-140, and an industry leader in Massachusetts predicted the proposal would pass the Senate if it emerges for a vote but face a veto from President Obama.
Clinical research company Veristat of Holliston has opened a new office in the Bay Area that will house the company's West Coast operations, it announced Monday.